Table 1 Patient characteristics of our study compared to SCHOLAR-1.

Characteristics	NCR cohort		SCHOLAR-1⁷
	N	(%)	N	(%)
Total no. of patients	197	(100)	636	(100)
Sex, male	125	(63)		64
Age, years
Median (min-max)	62 (18–81)		55 (19–81)
18–60	87	(44)		NA
61–69	64	(32)		NA
≥70	46	(23)		NA
Primary diagnosis
DLBCL	171	(87)		87
tFL	19	(10)		4
PMBCL	7	(4)		2
Indeterminate/ missing	0	(0)		7
Disease stage
I–II	36	(18)		27
III–IV	135	(69)		72
Unknown	26	(13)		<1
ECOG performance status
0–1	55	(28)		73
2–4	21	(11)		14
Unknown	121	(61)		13
IPI risk classification^a
Low	48	(24)		25
Low-intermediate	54	(27)		24
High-intermediate to high	95	(48)		33
Missing or incompletely assessed^b	119	(60)		18
R/R disease category
Primary refractory	97	(49)		28
Refractory to ≥second-line treatment	73	(37)		50
Relapsed ≤12 months post-autoSCT	27	(14)		22
Prior systemic therapy lines^c
1	97	(49)		28
2–3	73	(37)		49
≥4	0	(0)		<1
Center of treatment
Non-academic	131	(66)		NA
Academic	66	(34)		NA

DLBCL diffuse large B-cell lymphoma, tFL transformed follicular lymphoma, PMBCL primary mediastinal B-cell lymphoma, IPI International Prognostic Index, R/R relapsed or refractory, autoSCT autologous stem cell transplantation
^aIn the advent of a missing IPI risk parameter, that parameter was regarded as negative (i.e. no point assigned) in the NCR dataset. Therefore, an IPI score could be calculated for all patients.
^bPercentage of patients in whom one or more IPI risk parameters were missing or unknown.
^cSimilar to SCHOLAR-1, information on prior systemic therapy lines is only presented for the 86% (n = 170) of patients who were refractory to systemic therapy and not for the patients who relapsed post-autoSCT (n = 27). Percentages in the Table are shown as percentage of the total cohort (N = 197). Of the 170 patients who were refractory to systemic treatment, 57% (n = 97) received 1 prior systemic therapy line and 43% (n = 73) received 2-3 prior systemic therapy lines.

Search